SNAAT technology offers a rapid, cost-effective method for detecting SNPs using non-invasive samples like saliva. Designed for both decentralized and centralized settings, it provides high sensitivity and specificity, making it ideal for consumer health and personalized nutrition services.
SNAAT (Streamlined Nucleic Acid Amplification Technology) is a proprietary, LAMP-based method designed for the rapid and accurate detection of single nucleotide polymorphisms (SNPs) from non-invasive samples such as saliva and cheek swabs. This technology is particularly suited for point-of-care testing (POCT) as well as centralized laboratory settings, providing high sensitivity and specificity (≥95%) essential for consumer health applications and personalized nutrition services. SNAAT's fast turnaround time of under 30 minutes, coupled with its low cost per sample (≤$10), ensures a strong return on investment for high-volume applications.
Currently at TRL 5, SNAAT has undergone validation for analytical accuracy and compatibility with therapy-related SNPs. The technology is in the process of optimization and scale-up, with real-world field trials and regulatory preparations underway.
Genomtec is a clinical diagnostics technology company founded in 2016, specializing in innovative molecular diagnostic products and mobile genetic testing platforms, with headquarters in Wrocław, Poland, and an office in the UK.